IGF-1 Explained: The Biomarker Behind GH Secretagogue Research

Ask what a GH secretagogue "does" in the research literature and the honest answer usually comes back to one number: IGF-1. It is the readout used to tell whether the growth-hormone axis has actually been pushed, the marker that trials report, and the concept that ties together several otherwise different compounds. This article explains what IGF-1 is, how the signal travels, why researchers measure it rather than GH itself, and how the stocked compounds relate to it. It is a biomarker and mechanism explainer, not a product guide and not a how-to, and everything is written for laboratory research context only.

Growth & Performancegrowth

Growth hormone secretagogues and gonadotropins

What IGF-1 Actually Is

Insulin-like growth factor 1 is a small protein hormone structurally related to insulin. Although many tissues make some IGF-1 locally, the dominant source of the circulating (endocrine) pool is the liver, acting under the instruction of pituitary GH. Liver-specific deletion of the igf1 gene in mice sharply lowers circulating IGF-1, which established hepatic IGF-1 as the principal endocrine output of the GH axis (PMID 15645308). In research terms, that is why IGF-1 is treated as the axis's "output signal": when GH drive goes up, hepatic IGF-1 follows.

The GH to Liver to IGF-1 Axis

The signal travels in a defined sequence. The hypothalamus releases GHRH (and ghrelin-receptor input adds to it), which triggers pituitary somatotrophs to release GH in pulses, with somatostatin restraining the system. GH then acts on hepatic GH receptors to drive IGF1 gene transcription, and liver-specific deletion of the igf1 gene sharply lowers circulating IGF-1, which established the liver as the dominant source of the endocrine pool (PMID 15645308). Circulating IGF-1 in turn provides negative feedback on GH release, closing the loop, with IGF-1 at its output end.

Why Researchers Measure IGF-1 Instead of GH

Half-Life and the Binding-Protein Reservoir

Almost all serum IGF-1 is not free. It circulates bound to IGF-binding proteins, chiefly IGFBP-3, in a ternary complex with the acid-labile subunit (ALS). The binding proteins do two things at once: they greatly extend IGF-1's half-life relative to free IGF-1 and GH, and they modulate how much reaches the type-1 IGF receptor (IGF-1R) (PMID 7758431). This reservoir is the physical reason serum IGF-1 is stable enough to be a usable biomarker.

GH Secretagogues and Their IGF-1 Signature

The secretagogues below are studied for their ability to raise the subject's own GH, which in turn raises hepatic IGF-1, so IGF-1 serves as the shared downstream pharmacodynamic marker. Direct human IGF-1 data here exist for CJC-1295 DAC and tesamorelin; ipamorelin's supporting data are in vitro and animal. They differ in receptor, duration and how much human evidence exists.

Sermorelin is the acetate of GHRH(1-29), the short active fragment of GHRH. In non-GH-deficient short children, GHRH(1-29)NH2 raised mean height velocity from 4.8 to 7.2 cm per year over 12 months, showing that stimulating endogenous GH raises the downstream growth and IGF-1 readout (PMID 7955460).

CJC-1295 in its DAC form is a long-acting GHRH analogue. In healthy adults, a single dose of the DAC (drug-affinity-complex) version produced dose-dependent 2- to 10-fold rises in mean GH and 1.5- to 3-fold rises in IGF-1 lasting 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 staying above baseline up to about 28 days after repeated dosing (PMID 16352683). Importantly, that durable elevation is specific to the DAC form; the stocked CJC-1295 is the shorter "Mod-GRF(1-29)" no-DAC variant, which does not carry the same human duration data.

Tesamorelin is a stabilised GHRH analogue and the only approved molecule here: FDA-approved in the US for HIV-associated lipodystrophy, and not authorised in the EU. In a 412-patient randomised trial it reduced visceral adipose tissue by about 15.2 percent versus a 5.0 percent increase on placebo and raised IGF-1, with IGF-1 used as the pharmacodynamic marker (PMID 18057338); a later JAMA trial reproduced the visceral-fat and liver-fat effect with a rising IGF-1 (PMID 25038357).

Ipamorelin works through a different receptor. It is a selective ghrelin-receptor (GHS-R1a) agonist that releases GH with potency comparable to older GHRPs but, unlike GHRP-2 and GHRP-6, without materially raising ACTH, cortisol or prolactin (PMID 9849822). Its selectivity data are preclinical.

How IGF-1 LR3 Is Different

IGF-1 LR3 sits on the opposite side of the axis from a secretagogue. It is not a compound that raises GH; it is a modified IGF-1 molecule (a 13-residue N-terminal extension plus a Glu3-to-Arg substitution) that binds IGF-binding proteins very poorly. The original work concluded that reduced IGFBP binding, not stronger receptor affinity, explains its greater biological potency versus native IGF-1 (PMID 1311930), and in diabetic rats IGFBP-resistant variants were about 2.5 to 3 times more potent than native IGF-1 at restoring growth and nitrogen balance (PMID 7683875). Conceptually, LR3 acts directly at the IGF-1 receptor and does not depend on GH at all, so measuring IGF-1 as a biomarker of "axis drive" means something different for LR3 than for a secretagogue. There is no controlled human efficacy data for IGF-1 LR3, and this section is strictly mechanistic.

IGF-1 LR3growth

Long R3 variant of Insulin-like Growth Factor 1, modified for reduced IGFBP binding and ~20-30 hour half-life. Researched for cell proliferation, hypertrophy, and metabolic signaling. ≥98% purity.

What a Rising IGF-1 Does and Does Not Mean

A rising IGF-1 indicates sustained GH-axis drive over a longer window than a single GH reading, not a moment-to-moment GH level. But two honest caveats matter. First, IGF-1 is an imperfect single-point diagnostic: as a screening test for GH deficiency it performed poorly, with an area-under-the-curve of about 0.517 (PMID 34373538), so a single reading is a weak standalone signal. Second, IGF-1 is not inherently beneficial to push upward: chronically elevated IGF-1 has been associated with certain cancer risks in observational epidemiology (an association, not established causation). A higher number is not automatically a better one, which is exactly why this article frames IGF-1 as a laboratory biomarker rather than a target to chase.

Research Context and Responsible Framing

Every compound named here is a research chemical in this context, studied in vitro, in animals, or in specific clinical trial populations. Tesamorelin's approval is limited to HIV-associated lipodystrophy and does not generalise. GH secretagogues, IGF-1 and IGF-1 analogues are prohibited in sport under the WADA Prohibited List (class S2). Nothing here is dosing guidance, and IGF-1 is discussed as a biomarker of GH-axis activity, not a therapy endpoint. For the mechanism-level comparison of the secretagogues themselves, see the growth hormone peptides overview and GH secretagogues versus HGH.

Frequently Asked Questions

This article is for research and educational purposes only. IGF-1 is discussed as a laboratory biomarker of growth-hormone-axis activity. Nothing here is medical advice, a health claim, or a recommendation for use, and the trial data cited do not extend approved indications to the general population. All compounds mentioned are sold exclusively for laboratory research.